2025
Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Moteabbed M, Xing F, Beddok A, Lahoud R, Rozenblum L, Ding Z, Liu X, Grogg K, Woo J, Chen Y, Lim R, Ma C, Fakhri G. Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model. Physics And Imaging In Radiation Oncology 2025, 33: 100734. PMID: 40123775, PMCID: PMC11926426, DOI: 10.1016/j.phro.2025.100734.Peer-Reviewed Original ResearchGross tumor volumeSoft tissue sarcomasTissue sarcomasGross tumor volume delineationManual GTV delineationsMagnetic resonance imagingComputed tomographyFluorodeoxyglucose positron emission tomographyGTV delineationT1-weighted magnetic resonance imagingSingle-modePositron emission tomographyMulti-modal medical imagesTumor volumeIntra-reader variabilityFDG-PETTreatment planningSarcomaEmission tomographyImaging modalitiesResonance imagingDiffusion modelDice indexReader variabilityPatients
2023
Birth characteristics and risk of Ewing sarcoma
Wiemels J, Wang R, Feng Q, Yee A, Morimoto L, Metayer C, Ma X. Birth characteristics and risk of Ewing sarcoma. Cancer Causes & Control 2023, 34: 837-843. PMID: 37335392, PMCID: PMC10460323, DOI: 10.1007/s10552-023-01737-4.Peer-Reviewed Original ResearchConceptsBirth characteristicsEwing's sarcomaConclusionsThis population-based studyDisease riskMultivariable logistic regression modelNon-Hispanic white subjectsPopulation-based seriesPopulation-based studySignificant risk factorsMetastatic Ewing sarcomaEwing's sarcoma casesMinimal selection biasLogistic regression modelsYear of birthPurposeThe incidenceFetal growthRisk factorsSarcoma casesLower riskSarcomaMultiethnic populationBirth recordsWhite subjectsGenetic susceptibilityPredisposition allelesMyeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
de M, Wu L, Hirt C, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O, Group F. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leukemia & Lymphoma 2023, 64: 972-980. PMID: 36960680, DOI: 10.1080/10428194.2023.2185091.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaOverall survivalNPM1 mutationsDe novo acute myeloid leukemiaBone Marrow Pathology GroupMulti-institutional cohort studyNovo acute myeloid leukemiaRetrospective multi-institutional cohort studyShorter overall survivalPoor overall survivalFrequent cytogenetic abnormalityCohort studyMyeloid leukemiaPathology groupCytogenetic abnormalitiesComplex karyotypeUnique genetic landscapeMutations of genesGene mutationsSarcomaGenetic landscapeHigher average numberMutationsLeukemiaUterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Chu C, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Giuntoli R, Han E, Holmes J, Howitt B, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 181-209. PMID: 36791750, DOI: 10.6004/jnccn.2023.0006.Peer-Reviewed Original ResearchConceptsUterine neoplasmsNCCN guidelinesNCCN Clinical Practice GuidelinesPure endometrioid carcinomasUterine cancer casesClinical practice guidelinesFemale genital tractMesenchymal sarcomaEndometrial histologyEndometrioid cancerCommon malignancyEndometrial carcinomaUncommon subtypeEndometrioid carcinomaUterine cancerGenital tractCancer casesPractice guidelinesCarcinomaNeoplasmsCancerGuidelinesAdenocarcinomaEndometriumSarcomaUpdate of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone
Wang A, Maloney E, Al-Dasuqi K, Irshaid L, Ahmed A, Haims A, Porrino J. Update of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone. Skeletal Radiology 2023, 52: 1443-1463. PMID: 36656343, DOI: 10.1007/s00256-023-04286-8.Peer-Reviewed Original ResearchConceptsUndifferentiated small round cell sarcomaSmall round cell sarcomasBone tumorsRound cell sarcomasPediatric populationCell sarcomaMesenchymal tumorsHematopoietic neoplasmsWorld Health Organization classificationGiant cell-rich tumorsPediatric bone tumorsOsteogenic tumorsOrganization classificationVascular tumorsNotochordal tumorsTumorsGenetic sequencing techniquesChondrogenic tumorsCertain lesionsSoft tissueBoneSarcomaNeoplasmsSeparate manuscriptDetailed update
2022
Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma
Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems In Cancer Case Reports 2022, 8: 100202. DOI: 10.1016/j.cpccr.2022.100202.Peer-Reviewed Original ResearchNatural killer (NK) cell activityImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useSoluble IL-2 receptorCheckpoint inhibitor useImmune checkpoint inhibitorsCheckpoint inhibitor therapyCoffee-ground emesisIL-2 receptorPelvic osteosarcomaCheckpoint inhibitorsElevated ferritinInhibitor therapyHemophagocytic lymphohistiocytosisMetastatic sarcomaFailed treatmentElevated triglyceridesInhibitor useSarcoma patientsConventional therapyCell activationCancer treatmentPatientsSarcomaTherapyFeasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging
Shusharina N, Liu X, Coll-Font J, Foster A, Fakhri G, Woo J, Bortfeld T, Nguyen C. Feasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging. Physics In Medicine And Biology 2022, 67: 155013. PMID: 35817048, PMCID: PMC9344976, DOI: 10.1088/1361-6560/ac8045.Peer-Reviewed Original ResearchConceptsClinical target volumeSoft tissue sarcomasHealthy volunteersClinical target volume definitionClinical target volume delineationRight thighGross tumor volumeTarget volume definitionEcho-planar acquisitionsTarget volumeAuto-segmentationTumor volumeVolume definitionSarcoma patientsTissue sarcomasCT planeConvolutional neural networkT2-weightedCancer CenterPlanar acquisitionImaging sessionFat suppressionMR imagingSarcomaAnatomical orientation
2021
Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas
Marin T, Zhuo Y, Lahoud R, Tian F, Ma X, Xing F, Moteabbed M, Liu X, Grogg K, Shusharina N, Woo J, Lim R, Ma C, Chen Y, El Fakhri G. Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas. Radiotherapy And Oncology 2021, 167: 269-276. PMID: 34808228, PMCID: PMC8934266, DOI: 10.1016/j.radonc.2021.09.034.Peer-Reviewed Original ResearchConceptsGross tumor volumeRadiation therapy treatment planningGross tumor volume contoursGross tumor volume delineationTherapy treatment planningIntra-observer variabilityConsensus contoursGTV contoursPre-operative CT imagesSoft tissue sarcomasRadiation oncologistsTumor volumeBone sarcomasTreatment planningAccurate contoursCT imagesDelineation procedureSarcomaSoft tissueConfidence levelRadiationPatientsHausdorff distanceMultiple contoursX-ray1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
Gounder M, Patel M, Yamamoto N, Bauer T, Laurie S, Perez-Pitarch A, Geng J, Cheng J, Lahmar M, Lorusso P. 1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma. Annals Of Oncology 2021, 32: s1124-s1125. DOI: 10.1016/j.annonc.2021.08.878.Peer-Reviewed Original ResearchNCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 888-895. PMID: 34416706, DOI: 10.6004/jnccn.2021.0038.Peer-Reviewed Original ResearchProton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
Lee A, Kang J, Bernstein H, Marqueen K, Neal B, Kelly C, Dickson M, Tsai C, Tap W, Singer S, Alektiar K, Lee N. Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine 2021, 10: 4221-4227. PMID: 34085781, PMCID: PMC8267151, DOI: 10.1002/cam4.3646.Peer-Reviewed Original ResearchConceptsLocal progression-free survivalMetastatic sarcomaSystemic therapyQUAD ShotOverall survivalUnivariate analysisPalliative responseMedian local progression-free survivalGrade 3 acute toxicityFurther systemic therapyProgression-free survivalConcurrent systemic therapyProton therapyCommon histologyMedian followProton RTTreatment optionsRadiation therapyPatientsLocal controlSarcomaTherapyRegimenProton radiotherapyAcute toxicityGenomic Characterization of Radiation‐Induced Intracranial Undifferentiated Pleomorphic Sarcoma
Hong CS, Partovi E, Clune J, Huttner A, Park HS, Omay SB. Genomic Characterization of Radiation‐Induced Intracranial Undifferentiated Pleomorphic Sarcoma. Case Reports In Genetics 2021, 2021: 5586072. PMID: 33747576, PMCID: PMC7960067, DOI: 10.1155/2021/5586072.Peer-Reviewed Original ResearchComparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis
Yu K, Cahill S, Toombs C, Lindskog D. Comparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis. Pediatrics 2021, 147: 784-786. DOI: 10.1542/peds.147.3ma8.784.Peer-Reviewed Original ResearchComparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis
Yu K, Cahill S, Toombs C, Lindskog D. Comparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis. 2021, 784-786. DOI: 10.1542/peds.147.3_meetingabstract.784.Peer-Reviewed Original Research
2020
Avoiding Limb-Length Discrepancy with Reconstruction of a Massive Tibial Defect Using a Bone Allograft and a Minimally Invasive Lengthening System in a Pediatric Patient: A Case Report.
Alder KD, Morris MT, Hao Z, Li L, Yu KE, Lee FY. Avoiding Limb-Length Discrepancy with Reconstruction of a Massive Tibial Defect Using a Bone Allograft and a Minimally Invasive Lengthening System in a Pediatric Patient: A Case Report. JBJS Case Connector 2020, 10: e0456. PMID: 32649132, DOI: 10.2106/jbjs.cc.19.00456.Peer-Reviewed Original Research
2019
Rotational Tibio-Pelvic Constrained Hip Arthroplasty: A Surgical Technique: A Case Report.
Cahill SV, Yu KE, Dussik CM, Lee FY. Rotational Tibio-Pelvic Constrained Hip Arthroplasty: A Surgical Technique: A Case Report. JBJS Case Connector 2019, 9: e0404. PMID: 31703012, DOI: 10.2106/jbjs.cc.18.00404.Peer-Reviewed Original ResearchConceptsSoft tissue infectionsVan Nes rotationplastyExtensive debridementChronic boneHip disarticulationTissue infectionsFemur resectionDebridement proceduresRecurrent infectionsCase reportRight thighEpithelioid sarcomaSurgical techniqueHip arthroplastyIncurable infectionProsthetic hipInfectionRotationplastyResectionMultiple revisionsProsthetic devicesDebridementPatientsSarcomaArthroplastyAdjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatmentSarcomas in the United States: Recent trends and a call for improved staging
Gage MM, Nagarajan N, Ruck JM, Canner JK, Khan S, Giuliano K, Gani F, Wolfgang C, Johnston FM, Ahuja N. Sarcomas in the United States: Recent trends and a call for improved staging. Oncotarget 2019, 10: 2462-2474. PMID: 31069009, PMCID: PMC6497437, DOI: 10.18632/oncotarget.26809.Peer-Reviewed Original ResearchCause-specific mortalityMultivariable logistic regression modelEpidemiology of sarcomasEnd Results (SEER) databaseAppropriate surgical treatmentPatterns of careCases of sarcomaMajority of tumorsStandardization of careLogistic regression modelsCommon histologySurgical treatmentHistologic typeOverall incidenceResults databaseSurgical interventionTrue incidenceImproved stagingSarcoma casesSarcomaPrimary siteComprehensive national studyTreatment factorsHeterogeneous groupTumorsEtoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity
Brooks JP, Azmy V, Thompson A, Luon D, Prozora SD, Price C, Hsu FI. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity. Journal Of Oncology Pharmacy Practice 2019, 26: 228-231. PMID: 30885040, DOI: 10.1177/1078155219836478.Peer-Reviewed Original ResearchConceptsOrthopedic malignanciesHypersensitivity reactionsEtoposide phosphatePediatric patientsEtoposide hypersensitivityLarge academic medical centerAcademic medical centerCase of etoposideContinued therapyChart reviewFurther therapyFirst dosesFull dosesEwing's sarcomaMedical CenterPatientsMalignancySafe alternativeEtoposideHypersensitivityTherapyDiphenhydramineDosesPremedicationSarcoma
2018
Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB)
Miccio J, Jairam V, Gao S, Augustyn A, Oladeru O, Onderdonk B, Costa J, Han D, Khan S, Friedlaender G, Lindskog D, Deshpande H, Tara H, Osborn H, Roberts K, Patel K. Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB). International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e335. DOI: 10.1016/j.ijrobp.2018.07.1028.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply